SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction

The trials of SLGT2 inhibitors in type 2 diabetes suggested a potential benefit of these drugs in patients with heart failure. When randomized trials confirmed their benefit in heart failure with reduced ejection fraction , attention turned to heart failure with preserved ejection fraction (HFPEF). In the EMPEROR-Preserved trial the SGLT2 inhibitor empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure (HR 0.79 95%CI 0.69–0.9, P < .001). This was driven by a reduction in worsening HF events. SGLT2 inhibitors are likely to become the new standard of care in patients with HFPEF.